{"id":"tp-58725","type":"article-newspaper","title":"Lexeo Trial Data Leads Raymond James and Cantor Fitzgerald to Raise Targets","author":"Token Post","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/insights/58725","datePublished":"2026-11-16T19:13:15.000Z","dateModified":"2026-11-16T19:13:15.000Z","language":"en","abstract":"The target changes followed interim data from a Phase I/II trial of LX2020 for PKP2 arrhythmogenic cardiomyopathy. Raymond James views Lexeo as a strong buy.","section":"Insights & Views","references":[]}